Interpretation of Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa (2019) and its comparison with Guidelines for Drug-resistant Tuberculosis Chemotherapy in China (2019)

doi:10.3969/j.issn.1000-6621.2021.03.018

Abstract

Abstract:

To interpret the Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa (2019),including how to choose drugs,formulate treatment regimens as well as how to treat special patients, manage close contacts; and then to compare this South Africa Guidelines with the Guidelines for Drug-resistant Tuberculosis Chemotherapy in China (2019).

Key words: Tuberculosis,multidrug-resistant, Program evaluation, Guidelines, Comparative study, Comment

FENG Ying, REN Fei. Interpretation of Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa (2019) and its comparison with Guidelines for Drug-resistant Tuberculosis Chemotherapy in China (2019)[J]. Chinese Journal of Antituberculosis, 2021, 43(3): 295-298. doi: 10.3969/j.issn.1000-6621.2021.03.018

References 14

[1]	Health Department of the Republic of South Africa. Management of Rifampicnresistant Tuberculosis: A Clinical Reference Guide. Pretoria: Health Department of the Republic of South Atrica, 2019.
[2]	中国防痨协会. 耐药结核病化学治疗指南(2019年). 北京: 人民卫生出版社, 2019.
[3]	Nunn AJ, Phillips PPJ, Meredith SK, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med, 2019,380(13):1201-1213. doi: 10.1056/NEJMoa1811867. doi: 10.1056/NEJMoa1811867 URL pmid: 30865791
[4]	Balabanova Y, Fiebig L, Ignatyeva O, et al. Multidrug-resis-tant TB in Eastern region of the EU: is the shorter regimen an exception or a rule? Thorax, 2017,72(9):850-852. doi: 10.1136/thoraxjnl-2016-209841. doi: 10.1136/thoraxjnl-2016-209841 URL pmid: 28209653
[5]	Barry PM, Lowenthal P, True L, et al. Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. Am J Respir Crit Care Med, 2017,196(11):1488-1489. doi: 10.1164/rccm.201701-0013LE. doi: 10.1164/rccm.201701-0013LE URL pmid: 28665681
[6]	World Health Organization. WHO consolidated guidelines on tuberculosis. Geneva: World Health Organization, 2020.
[7]	邓国防, 张培泽, 杨敏, 等. 二线注射剂治疗耐多药结核病的现状与思考. 中国防痨杂志, 2019,41(6):604-608. doi: 10.3969/j.issn.1000-6621.2019.06.004.
[8]	Liu Q, Sun F, Li Y, et al. Practical considerations to implement the shorter regimen to MDR-TB patients in China. Clin Microbiol Infect, 2018,24(10):1035-1036. doi: 10.1016/j.cmi.2018.04.026. doi: 10.1016/j.cmi.2018.04.026 URL pmid: 29730223
[9]	Lange C, Dheda K, Chesov D, et al. Management of drug-resistant tuberculosis. Lancet, 2019,394(10202):953-966. doi: 10.1016/S0140-6736(19)31882-3. doi: 10.1016/S0140-6736(19)31882-3 URL pmid: 31526739
[10]	Harausz EP, Garcia-Prats AJ, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med, 2018,15(7):e1002591. doi: 10.1371/journal.pmed.1002591. doi: 10.1371/journal.pmed.1002591 URL pmid: 29995958
[11]	Zhao Y, Fox T, Manning K, et al. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retros-pective Cohort Study. Clin Infect Dis, 2019,68(9):1522-1529. doi: 10.1093/cid/ciy727. doi: 10.1093/cid/ciy727 URL pmid: 30165431
[12]	Collaborative Group for the Meta-Analysis of lndividual Patient Data in MDR-TB treatment-2017, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018,392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. doi: 10.1016/S0140-6736(18)31644-1 URL pmid: 30215381
[13]	World Health Organization. Intent tuberculosis infection:Updated and consolidated guildes for programmatic management. Geneva: World Health Organization, 2019.
[14]	World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.

[1]	Duan Hongfei, Tao Yong. Interpretation of social organization standard of Diagnosis Specification of Intraocular Tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 258-261.
[2]	Wu Qian, Wang Wei, Zhang Yu, Chen Songhua, Chen Bin. Construction of an evaluation indicator system for Zero Tuberculosis Community in Zhejiang Province [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 331-337.
[3]	Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Inspire-CODA Research Group. Expert consensus on the treatment of tuberculosis with contezolid [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 123-129.
[4]	Song Hongge, Liu Weigao, Chen Li. A comparative study on the therapeutic effects of total hip joint type spacer and pressure model spacer in patients with mid to late stage hip tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 562-566.
[5]	Zhao Yanli, Che Nanying. Interpretation of social organization standard of Specification for Pathological Diagnosis of Tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 371-374.
[6]	Li Ting, Liu Shuang, Wang Danxia, Lu Jia, Cheng Qianqian, Chen Chuang, He Jin’ge, Zhang Linglin, Xia Yong, Li Jing, Zhang Shu, Gao Wenfeng, Xia Lan. Evaluation of health economics of implementation of tuberculosis prevention and control program in Sichuan Province from 2011 to 2020 [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 333-339.
[7]	Gulina Badeerhan, Liu Nianqiang, Yipaer Aihaiti, Wang Le, Wang Senlu, Zulikatiayi Abudula, Wang Mingzhe, Zhang Jing, Wang Xinqi, Bi Hongbo. The effect of GeneXpert MTB/RIF detection technology in tuberculosis prevention and control program in Xinjiang [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 173-177.
[8]	Liu Shuren, Fu Lin, Wang Lianbo, Zhao Guisong, Li Zhuo, Dong Zhaoliang. Application of blood management in the perioperative period of lumbar tuberculosis under the concept of enhanced recovery after surgery [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1343-1349.
[9]	Ming Wenhua, Ma Tingting, Wang Hongtian, Wang Xueyan. Aspirin-exacerbated respiratory diseases: pathogenesis and treatment strategies [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1400-1405.
[10]	Sha Wei. Significance and challenges of the implementation of PAN-TB treatment strategy for tuberculosis prevention and control [J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1188-1192.
[11]	Song Ruixue, Wei Rongrong, Dong Jing, Jia Hongyan, Du Boping, Sun Qi, Xing Aiying, Li Zihui, Zhu Chuanzhi, Zhang Zongde, Pan Liping. The performance of interferon gamma-induced protein 10 mRNA detection technology in auxiliary diagnosis of tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 471-476.
[12]	Yan Xiaojing, Wang Qingfeng, Yang Yang, Chu Naihui, Nie Wenjuan. Diagnostic value of a nanopore sequencing assay of bronchoalveolar lavage fluid in smear-negative pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 487-492.
[13]	Fu Liang, Ren Tantan, Zhang Peize, Lu Shuihua. Interpretation of WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 336-348.
[14]	Liu Yueyuan, Su Wei, Zheng Jiangang, Wang Meng, Zeng Zhong, Huang Qin, Xie Tian, Li Renzhong. Study on the role of the prefectural tuberculosis designated hospital to improve the case finding of pulmonary tuberculosis in economic undeveloped areas of Jiangxi Province [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 279-284.
[15]	Yao Liming, Yao Xiaowei, Dong Zhaoliang, Liu Fengsheng, Wang Lianbo, Jia Chenguang. Diagnostic value of metagenomic next-generation sequencing in hip or knee tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 292-296.